Analyst Ratings For Hologic
Portfolio Pulse from Benzinga Insights
Analyst ratings for Hologic (NASDAQ:HOLX) show mixed sentiments with a recent shift towards bullishness. The average 12-month price target is now $80.5, down from $83.50. Analysts from Needham, UBS, Morgan Stanley, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market dynamics and Hologic's performance. Hologic, focusing on women's healthcare, faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management compared to industry averages.
February 02, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Hologic has received mixed analyst ratings with a recent shift towards bullishness. The average 12-month price target has been adjusted to $80.5. The company faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management.
The mixed analyst ratings with a recent bullish shift suggest uncertainty about Hologic's short-term stock price direction. The adjustments in price targets by analysts from Needham, UBS, Morgan Stanley, and RBC Capital indicate a reevaluation of Hologic's market position and performance. However, the company's challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management could dampen investor enthusiasm, leading to a neutral short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100